Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1563866 | 0.92 | CHEK1 (0.43) | KDM4ECHEK1CDK5CDK5R1CDK2AP1 | |
| SCHEMBL1562937 | 0.90 | CHEK1 (0.44) | KDM4ECHEK1CDK5CDK5R1CDK2AP1 | |
| SCHEMBL4994981 | 0.85 | CHEK1 (0.52) | CHEK1CDK2AP1 | |
| SCHEMBL4210048 | 0.84 | CHEK1 (0.44) | KDM4EPOLBCHEK1CDK2AP1 | |
| SCHEMBL4703508 | 0.83 | KDM4E (0.46) | KDM4EPOLBCHEK1MEN1KMT2A | |
| SCHEMBL5004723 | 0.82 | CHEK1 (0.53) | CHEK1CDK2AP1 | |
| SCHEMBL4994950 | 0.82 | CHEK1 (0.53) | CHEK1CDK2AP1 | |
| SCHEMBL5001102 | 0.81 | USP30 (0.43) | KDM4EPOLBCHEK1MEN1KMT2A | |
| SCHEMBL5001067 | 0.81 | CHEK1 (0.54) | CHEK1CDK2AP1 | |
| SCHEMBL4213189 | 0.80 | DYRK1A (0.46) | KDM4EPOLBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-20060281666-A1 | Substitute thiophenes and uses therof | ASTRAZENECA AB (SE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281666-A1 | Substitute thiophenes and uses therof | TYMP, TPMT, MGMT | KDM4E 3570/4885POLB 3068/4885LMNA 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.